These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1147 related articles for article (PubMed ID: 17954709)

  • 21. Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases.
    Têtu B; Brisson J; Lapointe H; Wang CS; Bernard P; Blanchette C
    Breast Cancer Res Treat; 1999 May; 55(2):137-47. PubMed ID: 10481941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Needle biopsy vs. conventional surgical biopsy - biochemical analysis of various prognostic factors].
    Kuner R; Pollow K; Lehnert A; Pollow B; Scheler P; Krummenauer F; Casper F; Hoffmann G
    Zentralbl Gynakol; 2000; 122(3):160-4. PubMed ID: 10756600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.
    Jorns JM
    Arch Pathol Lab Med; 2019 Dec; 143(12):1444-1449. PubMed ID: 31373514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Marguet S; Mazouni C; Ramaekers BL; Dunant A; Kates R; Jacobs VR; Joore MA; Harbeck N; Bonastre J
    Eur J Cancer; 2016 Aug; 63():168-79. PubMed ID: 27322916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.
    Yu H; Levesque MA; Khosravi MJ; Papanastasiou-Diamandi A; Clark GM; Diamandis EP
    Br J Cancer; 1996 Oct; 74(8):1242-7. PubMed ID: 8883411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biomarkers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1021-6. PubMed ID: 15272579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
    Dowsett M; Dunbier AK
    Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
    Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
    Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
    Van Poznak C; Tan L; Panageas KS; Arroyo CD; Hudis C; Norton L; Seidman AD
    J Clin Oncol; 2002 May; 20(9):2319-26. PubMed ID: 11981003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular testing in breast cancer.
    Paoletti C; Hayes DF
    Annu Rev Med; 2014; 65():95-110. PubMed ID: 24422569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 38. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
    Hammond ME; Hayes DF; Wolff AC
    J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545
    [No Abstract]   [Full Text] [Related]  

  • 40. [Contribution of biology to the therapeutic decision: cancer of the breast in 1995].
    Chinot O; Romain S; Martin PM
    Bull Cancer Radiother; 1995; 82(2):225-37. PubMed ID: 7546893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.